This trillionaire economy thrived in a global order Trump is ditchingThe nation's resilience, honed by history, is crucial as it navigates this uncertain era. Integration of Ukrainian refugees offers a potent...
Blow to Roche's cancer immunotherapy prospects as 2nd trial failsIn a study, a combination of tiragolumab and Roche's established Tecentriq drug did not slow disease progression in newly diagnosed cases o...
GSK, iTeos to develop cancer drug in up to $2 billion dealBoston-based iTeos will receive a $625 million upfront payment and is eligible to get up to $1.45 billion more if the programme meets certa...